Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib

NCT04327700 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Slow accruals

Conditions

Hepatocellular Carcinoma

Interventions

DEVICE: TheraBionic
DRUG: Regorafenib

Sponsor

Wake Forest University Health Sciences

Collaborators

[object Object]
[object Object]